Episode Details
Back to Episodes
Azenta's Q1 Misses, CEO Addresses Execution Issues
Description
Azentas Q1 results disappointed, with revenue falling short and adjusted EPS turning negative. The CEO attributed this to internal issues, customer spending hesitancy, particularly in North America, and competition. The companys Multiomics division underperformed due to softer demand, competition, and delayed equipment orders. However, recurring revenue streams like biorepositories provided some support. Azenta plans to streamline operations, make organizational changes, and watch for improvements in Multiomics, delayed capital equipment orders, and recurring revenue businesses.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/0cfced2341902371